文献速递肝病胰腺与胆道疾病消化道肿瘤与早癌

免疫检查点抑制剂诱导的胆管炎:药物警戒数据分析

Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-12-16

该研究分析法国药物警戒系统中免疫检查点抑制剂(ICI)诱导的胆管炎病例,旨在描述其临床特征、演变和结局。背景指出ICI相关不良事件可影响高达70%的患者,ICI诱导的胆管炎是新兴的免疫相关不良事件,欧洲肿瘤内科学会最新指南对其管理描述简略且证据不足。

要点

  • ICI相关不良事件可影响高达70%的患者,-checkpoint inhibitor-induced liver injury(CHILI)可发生于高达25%的患者。
  • ICI诱导的胆管炎是新兴的免疫相关不良事件,既往Pi等综述了53例已发表病例。
  • 胆汁淤积型CHILI与胆管损伤相关且缓解时间显著更长,对类固醇反应较差。

核心结论

  • 本研究旨在分析法国药物警戒系统中ICI诱导的胆管炎病例,以描述其临床特征、演变和结局。

研究设计与样本

  • 对法国药物警戒系统中报告的ICI诱导胆管炎病例进行分析。

主要发现

  • 原文未报告具体分析结果。

关键数值与推荐

  • ICI相关不良事件可影响高达70%的患者。
  • CHILI可发生于高达25%的患者。
  • Pi等综述了全部53例已发表的ICI诱导胆管炎病例并比较了不同胆管受累类型。
  • 胆汁淤积型CHILI与宏观和/或微观胆管损伤相关,且缓解时间显著更长。

临床怎么用

  • CHILI一线治疗使用类固醇,二线治疗使用免疫抑制药物。
  • 欧洲肿瘤内科学会最新指南纳入了胆管炎的管理,但内容简略且证据不足。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) are remarkable anticancer therapies that have revolutionized the oncological prognosis of many cancers.1 The considerable efficacy of ICIs is associated with the onset of more- or less-serious, immune-related adverse effects (irAEs) affecting several organs, which can concern up to 70% of patients, owing to a loss of self-tolerance during the restoration of antitumor immunity.2 Checkpoint inhibitor-induced liver injury (CHILI), which may occur in up to 25% of patients, is treated with steroids as first-line treatment, and immunosuppressive drugs as second-line treatment.3 Recently, ICI-induced cholangitis was described as an emerging irAE. Hence, Pi et al4 reviewed all 53 published cases of ICI-induced cholangitis and compared the different types of bile duct involvement. We recently described CHILI according to the biological profile: cholestatic, hepatocellular, or mixed.5 Cholestatic profiles were associated with macroscopic and/or microscopic bile duct damage, and time to resolution was significantly longer. More recently, Onoyama et al6 and Parlati et al7 described a poorer response to steroids in cases of biliary histologic damage or ICI-induced sclerosing cholangitis. The latest European Society for Medical Oncology guidelines include the management of cholangitis, which is succinct and still poorly documented.3 The aim of this study therefore was to analyze the cases of ICI-induced cholangitis reported in the French pharmacovigilance system to describe their clinical characteristics, evolution, and outcome.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Meunier L, Hountondji L, Jantzem H, et al. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data. Clin Gastroenterol Hepatol. 2023. PMID: 38110061. doi:10.1016/j.cgh.2023.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。